Clinical trials: CYP19
Arthralgia
Changes in Knee Articular Cartilage Volume in Women on Aromatase Inhibitors
Many women with breast cancer are treated with a class of drugs called aromatase inhibitors (mainly letrozole or anastrozole), which lowers the amount of estrogen being produced in the body.
- Trial name
- NCT00111241
- Testing
- aromatase inhibitors (letrozole, anastrozole)
- Where
- Australia
- Volunteers
- 115 people
- Sponsor
- Monash University
Arthralgia, Breast Cancer
Testosterone in Treating Postmenopausal Patients With Arthralgia Caused by Adjuvant Aromatase Inhibitor Treatment
This randomized phase III trial studies testosterone to see how well it works compared to placebo in treating postmenopausal patients with arthralgia (joint pain) caused by anastrozole or letrozole.
- Conditions
- Arthralgia, Breast Cancer, Hot Flashes, Musculoskeletal Complications
- Trial name
- NCT01573442
- Testing
- testosterone
- Where
- 529 sites in United States, Puerto Rico
- Volunteers
- 227 people
- Sponsor
- Alliance for Clinical Trials in Oncology
Breast Cancer
Gefitinib in Treating Patients With Metastatic Breast Cancer That Has Progressed After Antiestrogen and Nonsteroidal Aromatase Inhibitor Therapy
RATIONALE: Gefitinib may stop the growth of tumor cells by blocking the enzymes necessary for tumor cell growth. PURPOSE: Phase II trial to study the effectiveness of gefitinib in treating patients who have metastatic breast…
- Trial name
- NCT00066339
- Testing
- gefitinib
- Where
- Belgium
- Volunteers
- 44 people
- Sponsor
- European Organisation for Research and Treatment of Cancer - EORTC
is to Identify Biomarkers That Could Predict the Efficacy of an Adjuvant Letrozol Treatment in Postmenopausal Breast Cancer Patients.
Evaluation of Predictive Factors Regarding the Effectivity of Aromatase Inhibitor Therapy (PreFace)
Aromatase inhibitors have shown a superior efficacy compared to tamoxifen in the treatment of hormonal receptor positive breast cancer in postmenopausal patients.
- Trial name
- PreFace (NCT01908556)
- Testing
- Letrozole
- Where
- Germany
- Volunteers
- 3,545 people
- Sponsor
- Institut fuer Frauengesundheit
Breast Cancer, Low Bone Mineral Density
AMG 162 in the Treatment of Bone Loss in Subjects Undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer
The purpose of this trial is to evaluate AMG 162 in the treatment of bone loss in subjects undergoing Aromatase Inhibitor Therapy for Non-metastatic Breast Cancer.
- Conditions
- Breast Cancer, Low Bone Mineral Density, Osteopenia
- Trial name
- NCT00089661
- Testing
- AMG 162 / Denosumab
- Volunteers
- 252 people
- Sponsor
- Amgen
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8
Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS)
This study evaluates the effectiveness of a cognitive behavioral multicomponent treatment program in improving pain, mood, and functioning while reducing medication non-adherence in breast cancer patients with Aromatase Inhibitor…
- Conditions
- Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8
- Trial name
- NCT06106282
- Testing
- Non-Interventional Study
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- Mayo Clinic
Breast Cancer, Aromatase Inhibitor-induced Arthralgia
Efficacy of Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Aromatase Inhibitor-induced Arthralgia (AIA)
Breast cancer (BCa) is the most common cancer in women. The majority of BCa are hormone receptor positive and substantial benefits have been demonstrated for adjuvant endocrine therapies in reducing recurrence and extending…
- Trial name
- AROVAGUE (NCT07575750)
- Testing
- Active taVNS (TENS ECO Plus)
- Where
- France
- Volunteers
- 60 people
- Sponsor
- Institut Cancerologie de l'Ouest
Breast Cancer
NEOBREADS: Neoadjuvant Breast Diet Study
This is a feasibility trial of a 6-month extreme carbohydrate restricted diet (20 grams total carbs/day) via counseling with dietitian plus aromatase inhibitor therapy. Visits will occur at screening, mid-study, and pre-surgery.
- Trial name
- NEOBREADS (NCT03822715)
- Testing
- Carbohydrate restricted dietary intervention, standard of care aromatase inhibitors
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Monica Mita
Breast Cancer, Adjuvant Treatment
Evaluating the Use of a Medication 'Switch' vs Guideline-directed Interventions for Relieving Side Effects of Aromatase Inhibitors Among Breast Cancer Patients
Researchers have learned that about 50% of women do not finish the standard 5-year breast cancer treatment with an aromatase inhibitor.
- Conditions
- Breast Cancer, Adjuvant Treatment, Early Stage Breast Cancer
- Trial name
- SWIVEL (NCT07071038)
- Testing
- Switch, Guideline Directed Intervention (GDI)
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Neoplasms, Medication Adherence
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
Background: In women with hormone receptor positive (HR+) breast cancer, adjuvant endocrine therapy (AET) is associated with a significant survival advantage.
- Trial name
- NCT02876848
- Testing
- OPTIMUM e-health tool
- Where
- Canada
- Volunteers
- 120 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer
Zoledronic Acid in Aromatase Inhibitor Induced Musculoskeletal Symptoms
RATIONALE: Zoledronic acid may prevent bone loss and help prevent or lessen musculoskeletal symptoms in women receiving hormone therapy for breast cancer.
- Conditions
- Ductal Carcinoma in Situ, Estrogen Receptor-positive Breast Cancer, Progesterone Receptor-positive Breast Cancer, Stage I Breast Cancer
- Trial name
- NCT01194440
- Testing
- letrozole, zoledronic acid
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Breast Cancer
Writing Interventions in Breast Cancer Patients Taking Aromatase Inhibitors
Aromatase inhibitors are a powerful medication for reducing the risk of recurrence and increasing survival in postmenopausal breast cancer patients.
- Trial name
- NCT04651452
- Testing
- Value Affirmation, Reflective Journaling
- Where
- United States
- Volunteers
- 250 people
- Sponsor
- Carnegie Mellon University
Breast Cancer
A Pharmacokinetic and Randomized Trial of Neoadjuvant Treatment With Anastrozole Plus AZD0530 in Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
The investigators propose to conduct a Phase I/randomized Phase II study design in order to test the tolerability and efficacy of AZD0530 (also called saracatinib) when used together with anastrozole in therapy for ER+ and/or…
- Trial name
- NCT01216176
- Testing
- Anastrozole, AZD0530 (saracatinib)
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Joyce Marie Slingerland, MD
Atrophic Vaginitis, Breast Cancer
Serum Estradiol Levels In Postmenopausal Women With Breast Cancer Receiving Adjuvant Aromatase Inhibitors and Vaginal Estrogen
The purpose of this study is to see if Vagifem® 10mcg is safe for women who have had breast cancer. Vagifem is an estrogen product. It is a tiny tablet that is inserted into the vagina. It relieves vaginal dryness.
- Trial name
- NCT00984399
- Testing
- Vagifem® (vaginal 17β-estradiol) questionnaire & menopause symptom checklist
- Where
- 5 sites in United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Breast Cancer
Safety of Ovarian Stimulation With Letrozole and Gonadotropins in Breast Cancer Patients
Breast cancer patients are commonly treated with drugs that eggs present in the ovary and may reduce their chance for getting pregnant.
- Trial name
- NCT00504699
- Testing
- Ovarian stimulation in vitro fertilization cryopreservation
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- New York Medical College
Idiopathic Short Stature
Aromatase Inhibitors, Alone And In Combination With Growth Hormone In Adolescent Boys With Idiopathic Short Stature
When treating very short children in puberty we are time-limited, as sex hormones cause the growth plates to fuse and growth to end.
- Trial name
- ThrasherAI (NCT01248416)
- Testing
- Aromatase Inhibitor, Growth Hormone, Aromatase Inhibitor and Growth Hormone
- Where
- 4 sites in United States, Chile
- Volunteers
- 76 people
- Sponsor
- Nemours Children's Clinic
Hormone-sensitive, HER-2 Negative Metastatic Breast Cancer
Study of MEDI-573 Plus Standard Endocrine Therapy for Women With Hormone-sensitive Metastatic Breast Cancer
Study to evaluate the safety, tolerability, antitumor activity, and pharmacology of MEDI-573 in combination with an aromatase inhibitor (AI) in adult subjects with HR+, HER2-negative MBC.
- Trial name
- NCT01446159
- Testing
- MEDI-573, Aromatase Inhibitor
- Where
- 71 sites in United States, Belgium and 9 more
- Volunteers
- 188 people
- Sponsor
- MedImmune LLC
Breast Cancer
Cognitive Sequelae of Adjuvant Endocrine Therapy for the Treatment of Breast Cancer in Older Women
Breast cancer is the most frequently diagnosed cancer in women with the majority receiving an endocrine therapy (ET) in the adjuvant setting.
- Trial name
- NCT02480218
- Testing
- Neuropsychological test battery
- Where
- Canada
- Volunteers
- 47 people
- Sponsor
- Sunnybrook Health Sciences Centre
Sexual Dysfunction, Physiological
Vaginal Testosterone Cream vs ESTRING for Vaginal Dryness or Decreased Libido in Early Stage Breast Cancer Patients
The purpose of this clinical research study is to determine whether the ESTRING or a special preparation of a testosterone cream inserted vaginally are safe for use in breast cancer patients.
- Trial name
- E-String (NCT00698035)
- Testing
- Testosterone Cream, Estring
- Where
- United States
- Volunteers
- 76 people
- Sponsor
- University of California, San Francisco
Postmenopausal, Breast Cancer
Acupressure for Aromatase Inhibitor-Associated Musculoskeletal Symptoms in Patients With Breast Cancer
This is a randomized, double-blinded trial of self-acupressure to examine the effect of treatment on aromatase inhibitor (AI)-associated musculoskeletal symptoms (AIMSS) in postmenopausal women with breast cancer.
- Trial name
- NCT06228768
- Testing
- Acupressure
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Michigan Rogel Cancer Center